BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 21875802)

  • 1. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of 2-amino-6-(1H,3H-benzo[de]isochromen-6-yl)-1,3,5-triazines as novel Hsp90 inhibitors.
    Suda A; Kawasaki K; Komiyama S; Isshiki Y; Yoon DO; Kim SJ; Na YJ; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem; 2014 Jan; 22(2):892-905. PubMed ID: 24369839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis.
    Chang DJ; An H; Kim KS; Kim HH; Jung J; Lee JM; Kim NJ; Han YT; Yun H; Lee S; Lee G; Lee S; Lee JS; Cha JH; Park JH; Park JW; Lee SC; Kim SG; Kim JH; Lee HY; Kim KW; Suh YG
    J Med Chem; 2012 Dec; 55(24):10863-84. PubMed ID: 23186287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
    Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
    J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors.
    Suda A; Koyano H; Hayase T; Hada K; Kawasaki K; Komiyama S; Hasegawa K; Fukami TA; Sato S; Miura T; Ono N; Yamazaki T; Saitoh R; Shimma N; Shiratori Y; Tsukuda T
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1136-41. PubMed ID: 22192591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo[2,3-d]pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization.
    Davies NG; Browne H; Davis B; Drysdale MJ; Foloppe N; Geoffrey S; Gibbons B; Hart T; Hubbard R; Jensen MR; Mansell H; Massey A; Matassova N; Moore JD; Murray J; Pratt R; Ray S; Robertson A; Roughley SD; Schoepfer J; Scriven K; Simmonite H; Stokes S; Surgenor A; Webb P; Wood M; Wright L; Brough P
    Bioorg Med Chem; 2012 Nov; 20(22):6770-89. PubMed ID: 23018093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors.
    Musso L; Dallavalle S; Merlini L; Bava A; Nasini G; Penco S; Giannini G; Giommarelli C; De Cesare A; Zuco V; Vesci L; Pisano C; Castorina M; Milazzo F; Cervoni ML; Dal Piaz F; De Tommasi N; Zunino F
    Bioorg Med Chem; 2010 Aug; 18(16):6031-43. PubMed ID: 20655237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure based design of heat shock protein 90 inhibitors acting as anticancer agents.
    Doddareddy MR; Thorat DA; Seo SH; Hong TJ; Cho YS; Hahn JS; Pae AN
    Bioorg Med Chem; 2011 Mar; 19(5):1714-20. PubMed ID: 21306907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.
    Brough PA; Barril X; Borgognoni J; Chene P; Davies NG; Davis B; Drysdale MJ; Dymock B; Eccles SA; Garcia-Echeverria C; Fromont C; Hayes A; Hubbard RE; Jordan AM; Jensen MR; Massey A; Merrett A; Padfield A; Parsons R; Radimerski T; Raynaud FI; Robertson A; Roughley SD; Schoepfer J; Simmonite H; Sharp SY; Surgenor A; Valenti M; Walls S; Webb P; Wood M; Workman P; Wright L
    J Med Chem; 2009 Aug; 52(15):4794-809. PubMed ID: 19610616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect.
    Orosz A; Szabo A; Szeman G; Janaky T; Somlai C; Penke B; Bodor A; Perczel A
    Int J Biochem Cell Biol; 2006; 38(8):1352-62. PubMed ID: 16540363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
    Woodhead AJ; Angove H; Carr MG; Chessari G; Congreve M; Coyle JE; Cosme J; Graham B; Day PJ; Downham R; Fazal L; Feltell R; Figueroa E; Frederickson M; Lewis J; McMenamin R; Murray CW; O'Brien MA; Parra L; Patel S; Phillips T; Rees DC; Rich S; Smith DM; Trewartha G; Vinkovic M; Williams B; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5956-69. PubMed ID: 20662534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined pharmacophore and structure-guided studies to identify diverse HSP90 inhibitors.
    Sanam R; Tajne S; Gundla R; Vadivelan S; Machiraju PK; Dayam R; Narasu L; Jagarlapudi S; Neamati N
    J Mol Graph Model; 2010 Feb; 28(6):472-7. PubMed ID: 20005756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular design of anticancer drug leads based on three-dimensional quantitative structure-activity relationship.
    Huang XY; Shan ZJ; Zhai HL; Li LN; Zhang XY
    J Chem Inf Model; 2011 Aug; 51(8):1999-2006. PubMed ID: 21755987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.